Journal of Clinical Oncology - ASCO Publications
Oct 21, 2024 · A world where cancer is prevented or cured. Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or ...
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Oct 17, 2022 · Perioperative chemotherapy is recommended for a total preoperative and postoperative duration of 6 months, on the basis of total duration of chemotherapy in the EORTC 40983 trial. 64. Table 10. Perioperative Chemotherapy Versus Surgery Alone for Patients With Liver Metastases From Colorectal Cancer 22. Open in viewer.
Current and Future Management of HER2-Positive Metastatic …
Jun 2, 2021 · Advanced breast cancer with overexpression and/or amplification of human epidermal growth factor receptor 2 (HER2) is a clinically aggressive subtype with poor survival outcomes. 1,2 However, with the introduction of trastuzumab, the survival rates have greatly improved. 1 Trastuzumab binds to the extracellular domain IV of HER2 preventing its …
Management of Immune-Related Adverse Events in Patients …
Immunotherapy has revolutionized the treatment of many different types of cancers. Immune checkpoint inhibitors (ICPis) targeting cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4), programmed cell death-1 (PD-1), and PD ligand 1 (PD-L1) work by preventing the receptors and ligands from binding to each other, thereby disrupting signaling so that T cells can recognize …
When a Monoclonal Gammopathy Is Not Multiple Myeloma
Apr 8, 2022 · A monoclonal gammopathy is a laboratory-based finding that is being increasingly recognized in the aging population. Until recently, the incidence of monoclonal gammopathy of undetermined significance (MGUS) was based on studies from Olmsted County, Minnesota, and from Scandinavian health records, indicating an incidence of approximately 1%. 1 The majority …
Management of Stage III Non–Small-Cell Lung Cancer: ASCO …
Dec 22, 2021 · Introduction. The purpose of this guideline is to help clinicians involved in the diagnosis and treatment of lung cancer accurately confirm the presence of stage III non–small-cell lung cancer (NSCLC) and offer the most appropriate treatments.
ASCO Publications
ASCO’s publications—including the Society’s flagship publication, the Journal of Clinical Oncology —serve readers as the most credible, authoritative, peer-reviewed resources for significant clinical oncology research that informs the delivery of high-quality patient care across the globe. Explore the first articles from the new JCO ...
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO ...
Kidney cancer will be diagnosed in 79,000 US patients in 2022 (50,290 men and 28,710 women) and will account for 13,920 deaths (8,960 men and 4,960 women). 1 Clear cell renal cell carcinoma (ccRCC) is the most common subtype of RCC, and it continues to be a major source of morbidity and mortality. 1,2 This disease has been a bellwether tumor type, with novel classes …
Management of Cancer Therapy–Associated Oral Mucositis
Feb 3, 2020 · Abstract. Mucositis is a common and feared complication of anticancer therapy that can affect up to 90% of certain populations of patients with cancer. Even seemingly uncomplicated mucositis, which is often self-limited, can result in intense patient discomfort and decline in quality of life. Severe mucositis can be complicated by uncontrolled ...
Evidence-Based Management of Oral Mucositis | JCO Oncology …
Feb 3, 2020 · The morbidity of oral mucositis includes pain, nutritional compromise, and infection risk, which potentially result in breaks or dose reductions in cancer therapy. Historically, management was focused mainly on pain control and nutritional support. However, evidence-based clinical practice guidelines for oral and GI mucositis were recently updated.